LUNG DISEASES, INTERSTITIAL

This study looked at the long-term safety of nintedanib in children and teens with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred. Fifty-four participants took nintedanib capsules twice daily for at least 1.5 to 3 years. The goal was to see how…

This study tested a new medicine called BI 1015550 in 1178 adults with progressive fibrosing interstitial lung diseases (PF-ILDs), a group of conditions that cause lung scarring and make breathing harder. Participants took either a low dose, a high dose, or a placebo (fake pill) …

This study looked at the safety of the drug Ofev in 425 Japanese patients with a type of progressive lung scarring called PF-ILD. The main goal was to track any side effects, especially liver problems, in everyday medical practice. The study did not test if the drug works, but ra…

This study involved over 1,300 adults with rheumatoid arthritis who had at least two risk factors for interstitial lung disease (ILD), such as being male, a smoker, or older at diagnosis. Researchers used CT scans to check for ILD and created a prediction model to help doctors de…

This study looked at whether people with chronic lung disease who experience drops in oxygen during exercise can walk just as far without using supplemental oxygen as they can with it. Forty adults with stable lung disease completed a 6-minute walk test both with and without nasa…

This study followed 158 adults with a progressive form of lung scarring (not IPF) who were starting the medication nintedanib. Researchers wanted to see if changes in lung function over 52 weeks were linked to changes in cough and shortness of breath, as reported on a special que…